Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 3/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR1F | P30939 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.35 |
| ▸ | SCD | O00767 | 3/20 | 0.35 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18399275 | 0.82 | RXRA (0.48) | CYP2A6PIK3CD | |
| SCHEMBL2980192 | 0.82 | ALDH1A1 (0.40) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL2980189 | 0.82 | ALDH1A1 (0.40) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL17677989 | 0.77 | PIK3CD (0.41) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL30778591 | 0.77 | KDM4E (0.43) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL2980987 | 0.77 | PIK3CD (0.41) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL17678157 | 0.77 | KMO (0.41) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL19698021 | 0.76 | PIK3CD (0.41) | PDE9AHTR1AHTR1BHTR1FPIK3CD | |
| SCHEMBL7419168 | 0.75 | HCAR3 (0.56) | PDE9AHTR1AHTR1BHTR1F | |
| SCHEMBL30778513 | 0.74 | MAPT (0.46) | HTR1AHTR1BHTR1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781460-B2 | Substituted indazoles as inhibitors of phosphodiesterase type-IV | RANBAXY LABORATORIES LIMITED (IN) | 2010-08-24 | — | — | US | disclosed |
| US-20080312285-A1 | Substituted Indazoles as Inhibitors of Phosphodiesterase Type-Iv | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312285-A1 | Substituted Indazoles as Inhibitors of Phosphodiesterase Type-Iv | PDE3B, PDE3A, PDE7A | PDE9A 14/4885CYP2A6 2265/4885HTR1A 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.